文献速递类风湿关节炎

早期活动性类风湿关节炎患者以低疾病活动度或DAS缓解为治疗目标的比较

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis.
PubMed 文献 · RMD Open · 2018-05-20

比较133例以DAS≤2.4(低疾病活动度)为目标的早期活动性RA患者与175例以DAS<1.6(缓解)为目标的早期RA患者的5年结局。两组DAS下降、功能能力和影像学损伤进展相似,但DAS<1.6组更多患者达到DAS<1.6、Boolean缓解和停药后DAS缓解。

要点

  • 以DAS<1.6为目标与第1年达到DAS<1.6(OR 3.04)和Boolean缓解(OR 3.03)相关。
  • 以DAS<1.6为目标与第5年停药后DAS缓解相关(OR 3.77)。
  • 两组DAS下降、功能能力和影像学损伤进展随时间相似。

核心结论

  • 在开始接受可比改善病情抗风湿药联合泼尼松治疗的早期活动性RA患者中,后续以DAS<1.6为目标治疗与以DAS≤2.4为目标治疗相比,随时间推移的临床和影像学结局相似;但DAS<1.6目标组更多患者达到缓解和停药后缓解。

研究设计与样本

  • 比较133例以DAS≤2.4为目标的早期活动性RA患者(1987年标准,起始甲氨蝶呤、柳氮磺吡啶和逐渐减量高剂量泼尼松,来自BeSt研究第3组)与175例以DAS<1.6为目标的早期RA患者(起始甲氨蝶呤和逐渐减量高剂量泼尼松,选自IMPROVED研究中符合BeSt研究入选标准者)的5年结局。

主要发现

  • 基线时DAS<1.6目标组患者疾病较DAS≤2.4目标组更轻(平均DAS 4.1±SD 0.7 vs 4.4±0.9,p=0.012)且影像学损伤更少。
  • 两组随时间DAS下降、功能能力和影像学损伤进展相似。
  • 两组达到DAS≤2.4的患者百分比相似,但DAS<1.6目标组更多患者达到DAS<1.6和停药后DAS缓解。
  • 以DAS<1.6为目标治疗与第1年达到DAS<1.6(OR 3.04,95%CI 1.64至5.62)和Boolean缓解(OR 3.03,95%CI 1.45至6.33)相关,并与第5年停药后DAS缓解相关(OR 3.77,95%CI 1.51至9.43)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare outcomes of targeted treatment aimed at either low disease activity or remission in patients with early active rheumatoid arthritis (RA). METHODS: Five-year outcomes were compared in 133 patients with early active RA (1987), starting with methotrexate, sulfasalazine and tapered high dose of prednisone (arm 3 of the BehandelStrategieën (Treatment Strategies for Rheumatoid Arthritis) (BeSt) study), targeted at Disease Activity Score (DAS) ≤2.4 (low disease activity), and 175 patients with early RA, starting methotrexate and tapered high dose of prednisone, targeted at DAS <1.6 (selected from IMPROVED study who would have fulfilled inclusion criteria of the BeSt study). Association of treatment target with outcomes DAS <1.6, Boolean remission at year 1 and drug-free DAS remission (DFR) at year 5 were analysed by logistic regression analysis. RESULTS: At baseline, DAS <1.6 steered patients had a milder disease than DAS ≤2.4 steered patients (mean DAS 4.1±SD 0.7vs4.4±0.9, p=0.012) and less radiological damage. DAS decrease, functional ability and radiological damage progression over time were similar in both patient groups. DAS ≤2.4 was achieved in similar percentages in both patient groups, but more DAS <1.6 steered patients achieved DAS <1.6 and DFR. DAS <1.6 steered treatment was associated with achieving DAS <1.6 (OR 3.04 (95% CI 1.64 to 5.62)) and Boolean remission (3.03 (1.45 to 6.33)) at year 1 and DFR at year 5 (3.77 (1.51 to 9.43)). CONCLUSIONS: In patients with early active RA who start with comparable disease-modifying antirheumatic drug+prednisone combination therapy, subsequent DAS <1.6 steered treatment is associated with similar clinical and radiological outcomes over time as DAS ≤2.4 steered treatment; however, in the DAS <1.6 steered group, more patients achieved remission and drug-free remission.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Akdemir G, Markusse IM, Bergstra SA, et al. Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis. RMD Open. 2018. PMID: 29862045. doi:10.1136/rmdopen-2018-000649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。